Treatment with L-DOPA is a commonly used therapy in Parkinson's disease. The treatment is based on replacement of the reduced striatal dopamine levels, which occurs when the dopamine neurons in the substantia nigra undergo degeneration. After long-term L-DOPA therapy, the patients develop motor complications. These involve motor fluctuations and abnormal involuntary movements or L-DOPAinduced dyskinesia (Yahr 1970; Granérus 1978) . Approximately 40% of the patients develop dyskinesia within 4 years of L-DOPA treatment, and the number of affected patients increases over time (Ahlskog and Muenter 2001) . Thus, L-DOPA-induced dyskinesia is a severe side effect affecting many patients as the disease progresses.
. The mechanism behind dyskinesia is believed to be due to the site for conversion of L-DOPA to dopamine. Hence, L-DOPA itself may not produce dyskinesia without first being converted to dopamine (Carta et al. 2006; Buck and Ferger 2008) . The conversion of L-DOPA to dopamine is catalyzed by the enzyme aromatic amino acid dopa decarboxylase (AADC). Thus, increased striatal levels of AADC promote dyskinetic behavior and blocking this enzyme prevents involuntary movements (Bankiewicz et al. 2006; Buck and Ferger 2008) . In the striatum, AADC is expressed in the dopamine nerve terminals as well as in the serotonergic neurons (Arai et al. 1995; Yamada et al. 2007) . Therefore, it has been suggested that L-DOPA is converted to dopamine in serotonergic nerve fibers when the dopaminergic nerve fibers have degenerated (Arai et al. 1995; Carta et al. 2007; Yamada et al. 2007) . Dopamine would in this case be released as a false transmitter together with serotonin. Because of absence of dopamine autoreceptors there is no normal feed-back regulation of the dopamine release, which then has become one hypothesis for development of dyskinesia. This hypothesis is supported by data demonstrating that a serotonergic hyperinnervation of the dopaminedepleted striatum, as seen in animals grafted with serotonergic neurons, exacerbates dyskinesia, while a serotonergic denervation abolishes this behavior (Carta et al. 2006; Carlsson et al. 2007) . Based on these studies, the development of dyskinesia is believed to occur when dopamine lesions are severe Carlsson et al. 2009 ).
To counteract dyskinesia in patients, a serotonin autoreceptor (5-HT 1A receptor) agonist was given to advanced parkinsonian patients. The dyskinesia was successfully reduced without affecting the positive effect of L-DOPA (Bara-Jimenez et al. 2005) . The mechanism has been contributed to reduced release from the serotonergic nerve fibers, and consequently reduced release of dopamine as the false transmitter, which also was confirmed in the animal model of dyskinesia, where 5-HT 1A receptor agonists can counteract dyskinesia in dopamine-denervated animals (Kannari et al. 2001; Carta et al. 2007 ). However, contradictory results demonstrate that L-DOPA-induced dyskinesia is not correlated to dopamine degeneration, neither in monkey experiments nor in patients (Guigoni et al. 2005; Linazasoro et al. 2009; Lunardi et al. 2009 ). Furthermore, all unilaterally dopamine-depleted rats do not develop dyskinesia upon L-DOPA treatment, even though they all are severely dopamine-depleted (Lundblad et al. 2009 ). Therefore, the effect of L-DOPA-derived dopamine in dopaminedepleted striatum is still elusive.
High-speed in vivo chronoamperometry is an efficient technique to study extracellular dopamine levels, where dopamine release and clearance can be monitored in subsecond time resolution (van Horne et al. 1992) . Thus, the technique can monitor the release of dopamine after conversion from L-DOPA. In the present study, potassiumevoked extracellular dopamine release and clearance was measured upon local administration of L-DOPA utilizing in vivo chronoamperometry in the striatum of unilaterally dopamine-depleted and dopamine/serotonin-denervated rats. Furthermore, recordings were performed in animals with established L-DOPA-induced dyskinesia to study how dopamine release is affected upon chronic L-DOPA treatment.
Material and methods

Animals
Young adult female Sprague-Dawley rats (B&K, Sollentuna, Sweden) were used throughout the study. The animals were housed under a 12 : 12 h light-dark cycle and provided with free access to food and water. All experiments had been approved by the local ethics committee.
Study design
The study includes bilateral in vivo electrochemical recordings of extracellular dopamine in the striatum of normal animals (n = 4), unilaterally dopamine-lesioned animals (n = 10), unilaterally dopamine/serotonin-lesioned animals (n = 4), and unilaterally dopaminelesioned and L-DOPA treated animals expressing dyskinesias (n = 5; Fig. 1a ).
Dopaminergic and serotonergic lesions
Unilateral lesion of the nigrostriatal dopamine system was performed in the right hemisphere with stereotaxic injection of 6-hydroxydopamine (6-OHDA; Sigma, Stockholm, Sweden) under isofluran anesthesia (Baxter Medical, Kista, Sweden). 6-OHDA was administered as one single injection into the medial forebrain bundle (4 lL of 2 lg/lL in 0.9% NaCl containing 0.02% ascorbic acid) at a rate of 1 lL/min. Coordinates used (in mm from bregma) were anterior-posterior (AP): )4.4, medial-lateral (ML): )1.2, and )7.8 mm below the dural surface (DV). Tooth bar was set at )2.3 mm.
The neurotoxin 5,7-dihydroxytryptamine (5,7-DHT; Sigma) was utilized to produce the serotonergic denervation in unilaterally dopamine-depleted animals, after being screened for high success of dopamine depletion. Animals were injected with 5,7-DHT into the right lateral ventricle at coordinates (in mm from bregma): AP: +0.5, ML: )1.2, DV: )4.5 mm, and tooth bar set at )3.3 mm. Each animal received 100 lg 5,7-DHT (10 lg/lL in 0.9% saline containing 0.02% ascorbic acid) at a rate of 1 lL/min. After neurotoxin injection, the syringe was left in the brain for 3 min prior to retraction.
Rotational behavior
Apomorphine-induced rotations were performed to screen for severe striatal dopamine lesions. Turning behavior, in terms of contralateral rotations to the denervated striatum, was registered after subcutaneous injection of apomorphine (0.05 mg/kg). Turning behavior was monitored for 70 min and animals rotating 450 turns or more were selected for further studies, which corresponds to at least a 90% of dopamine depletion (Hudson et al. 1993) .
Dyskinesia ratings
Unilaterally dopamine-depleted animals screened for severe dopamine lesion were selected for chronic L-DOPA treatment. Rats received daily subcutaneous injections of 4 mg/kg L-DOPA (Sigma) combined with 15 mg/kg benserazide-hydrochloride (Sigma) for 14 days. The drugs were dissolved in 0.9% NaCl in a volume of 2 mL/kg body weight. The animals were screened for the development of abnormal involuntary movements (AIMs) and rated at days 1, 4, 7, 10, and 14 according to the validated basic rating scale used in previous studies (Cenci et al. 1998; Lundblad et al. 2002) . During rating sessions, animals were scored once every 20 min during 1 min for the expression of axial, forelimb, and orolingual AIMs. Each subtype was rated from 0 to 4 depending on its severity and persistence (1 = occasional, 2 = frequent, 3 = continuous but interrupted by sensory distraction, 4 = continuous, not interrupted by sensory distraction). Animals were rated at 20-180 min after the time of injection, thus resulting in nine observations of each animal. For detailed description of rating procedures, see Cenci and Lundblad (2007) . Animals displaying scores of ‡ 2 on at least two of the three subtypes of AIMs were considered as dyskinetic and included in the study, and those with scores of 0-1 on each AIMs subtype were excluded. Following the 14 days of chronic L-DOPA treatment, rats were given 2-3 injections per week and rated every 10th day to assure stable status of dyskinesias. Electrochemical recordings were initiated after the first 10-day period and were finished within four weeks from this time point. All animals received a regular dose of L-DOPA two days before electrochemical recordings.
In vivo chronoamperometry
To study L-DOPA conversion after local application into the striatum, in vivo electrochemistry was employed. The recordings were performed using the Fast Analytical Sensing Technology (FAST-16) system (Quanteon, Nicholasville, KY, USA; Hoffman and Gerhardt 1998) . Single carbon fiber electrodes (Quanteon) were utilized, enabling second-by-second measurements of extracellular levels of electrochemically active compounds. Electrochemically active compounds refer to compounds that can undergo oxidation and reduction. A square wave potential of 0.55 V, with a resting state at 0 V, was applied at a rate of 5 Hz to the carbon fiber electrode, causing oxidation and subsequent reduction of surrounding analytes.
Oxidation and reduction currents were integrated, thus giving an average signal per second. Increased extracellular levels of electrochemically active compounds induce a rapid change in the current recorded by the electrode that is directly proportional to analyte concentration (Scatton et al. 1988) . Hence, each increment of analyte concentration results in a peak formation, in which the highest point (calculated from the baseline) corresponds to the maximum peak amplitude (lM). Analytes were identified by red/ox ratios, that is, 0.8 for dopamine and 0.2 for serotonin (Strömberg et al. 1991) .
Prior to measurements, the carbon fiber electrodes were coated with Nafion (Sigma) to enhance the selectivity for catecholamines. Nafion is a teflon-derivate that repels anions such as ascorbic acid, whilst it concentrates cations as dopamine at the electrode surface. Calibration of the electrodes was performed using standard solutions of ascorbic acid and dopamine, and electrodes with high selectivity for dopamine were used (Gerhardt et al. 1984) . The carbon fiber electrodes included in the present study had selectivity ratios of more than 200 : 1 for dopamine over ascorbic acid, a limit of detection of < 0.05 lM for dopamine with a linearity (R 2 ) of > 0.995.
Following calibration, the carbon fiber electrodes were mounted parallel with two glass micropipettes (130-160 lm distance between the tips and the electrode), using sticky wax. The micropipettes were filled with KCl (120 mM) and L-DOPA (2.5 or 12.5 mM; Sigma) solutions, respectively, and connected to a micropressure system that allows precise volume ejections into the brain. In addition, control experiments were performed where saline (0.9% NaCl) was ejected instead of L-DOPA. The ejected volume was monitored using a scale fitted in the ocular of an operation microscope.
The rats were anesthetized with urethane (1.25 g/kg) and tracheotomized to facilitate spontaneous breathing. The skull was fixed in a sterotaxic frame, the scalp removed, and the bone overlying the striatum was bilaterally removed using a dental drill. A single burr hole for implantation of an Ag/AgCl reference electrode was made caudally to the striatum. Body temperature was maintained during recordings by keeping the animals on a heating pad.
The reference electrode was implanted into the brain and the electrode/pipette assembly was lowered into the striatum using a microdrive. The recordings were performed in the striatum at the following coordinates (in mm, calculated from bregma): AP: 0 and +1.0, ML: ± 2.6, and at three different depths from the brain surface ()3.5, )4.5, )5.5 mm) at each track. The hemisphere and striatal location for the first measurements was alternated between each animal and balanced within groups. KCl (240 nL) was ejected twice before and twice after L-DOPA (240 nL in intact, and 480 nL in lesioned striatum) ejection in intervals of 5 min, and the first KClevoked release upon L-DOPA ejection was studied 10 min after application of L-DOPA (Fig. 1b) .
Immunohistochemistry
Following electrochemical recordings, the brains were rapidly removed and immersion fixed in 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) for 24 h. After fixation, the brains were thoroughly rinsed in 10% sucrose in 0.1 M phosphate buffer until the brains had sunk in the sucrose solution, before being freezed and cryostat sectioned into 14 lm thick sections. The sections were then thawed onto chromealun-gelatin-coated glass slides.
Prior to primary antibody incubation, brain sections were rinsed in phosphate-buffered saline (PBS; pH 7.4). Thereafter, sections were incubated with primary antibodies raised against tyrosine hydroxylase (TH, mouse anti-TH, diluted 1 : 1500; DiaSorin, Sundbyberg, Sweden), the serotonin transporter (SERT, mouse anti-SERT diluted 1 : 100; Millipore AB, Solna, Sweden) or aromatic amino acid dopa decarboxylase (AADC, rabbit anti-AADC, diluted 1 : 100; Millipore AB). Alexa Fluor Ò conjugates (A594 goat anti-mouse or A488 goat anti-rabbit, diluted 1 : 500; Molecular Probes Inc., Eugene, OR, USA) were used as secondary antibodies. All antibodies were diluted in PBS. For TH, AADC, and secondary antibodies, 0.3% Triton-X-100 was added to the solution. Preceding SERT antibody incubation, sections were incubated with 10% fetal calf serum diluted in 0.3% Triton-X-100 in PBS for 1 h at 21°C. After blocking, the sections were quickly rinsed in PBS. Primary antibody incubations were performed for 48 h at 4°C. A second serum block using 5% goat serum was performed before incubation with secondary antibodies. The goat serum was diluted in PBS and applied for 15 min at 21°C. The blocking solution was gently tipped off after incubation and secondary antibodies were applied. All antibody incubations were performed in a humid chamber and sections were rinsed three times in PBS between incubations. Sections were cover-slipped in 90% glycerol in PBS.
Image analysis TH-and SERT-positive nerve fiber densities were evaluated to ensure successful lesions. SERT-positive nerve fiber density was measured at recording sites of all groups to evaluate possible differences. The density of SERT-immunoreactivity was measured bilaterally in the striatum using the NIH Image software. Images of the sections were captured using a digital camera (Jenoptic, Jena, Germany) connected to a fluorescence microscope. Before analysis, the images were made binary and the density measurements were performed in a set frame. Measurements were performed over three dorsoventrally different areas in the dorsal striatum at two different rostro-caudal sites in each hemisphere, corresponding to the recording sites, i.e. 6 measurements per side and animal. The density evaluations were expressed as mean grey values.
Statistical analysis
Electrochemical recordings were performed at two distinct striatal positions (at bregma level and 1 mm anterior from bregma level) in both hemispheres of each rat and at three depths (3.5, 4.5, and 5.5 mm) below the brain surface at each position. Statistical analysis revealed no differences in dopamine release when comparing measurements performed at the different striatal recording sites and dorsoventral depths in the normal striatum. Data are therefore presented as an average value for measurements made in normal, lesioned, or intact striata of each group, independent of the recording site. A previous study supports this approach (Lundblad et al. 2009 ). Furthermore, to investigate how a local ejection into the striatum affects the dopamine release and whether the response is deteriorating over the duration of time, saline (0.9% NaCl) was applied into the intact and dopamine-lesioned striatum.
To compare events within and between groups, the parameters dopamine peak amplitude (lM), onset time (T rise , seconds) and reuptake (T 50 , seconds) are presented. Dopamine concentration is defined as the maximum peak value calculated from the baseline following KCl ejection. The onset time (T rise ) is defined as the time (in seconds) for peaks to reach maximal amplitude and the reuptake (T 50 ) as the time (in seconds) needed for the peak amplitude to decrease 50% from the maximal concentration. Mean values were calculated for parameters, separated with regard to treatment (group), the sequence order of KCl evoked release and whether it was performed before or after L-DOPA. Release amplitude in the lesioned striata was at the lowest levels around 100 nM, and at this low level T rise and T 50 are difficult to determine and were therefore not presented. Furthermore, SERT-positive nerve fiber density values and the number of AADC-positive neurons in the striatum were compared between treatment groups.
Data were analyzed using one-or two-factor analysis of variance (ANOVA). Two-factor ANOVA was performed to assess interactions between two independent factors. To detect differences within and between individual groups, one-factor ANOVA was performed followed by Bonferroni post hoc comparison. All results are expressed as mean ± SEM. The significance level was set at p < 0.05.
Results
Comparisons within animal lesion models To study the extracellular dopamine release upon locally applied L-DOPA, potassium-evoked dopamine peak amplitudes were monitored in the striata of normal, intact and lesioned sides of dopamine-, dopamine/serotonin-depleted, and dopamine-lesioned animals chronically treated with L-DOPA. KCl was ejected twice before and after local L-DOPA injection with 5-min intervals. The second stimulation was performed to study recovery capacity after the first evoked release. After L-DOPA ejection, 10 min was let to pass before stimulating transmitter release (Fig. 1b) . To evaluate KCl-evoked dopamine release upon L-DOPA administration in the lesioned striatum, higher L-DOPA concentration was needed than in the normal striatum. Therefore, 12.5 mM (480 nL) and 2.5 mM (240 nL) L-DOPA was applied to the lesioned and intact striata, respectively.
When comparing dopamine release upon the first and second KCl ejection before L-DOPA application, no statistical differences in extracellular dopamine peak amplitudes were found in any of the treatments included (normal p = 0.326, intact side of dopamine-lesioned p = 0.898, dopamine-lesioned p = 0.432, dopamine/serotonin-lesioned p = 0.210, intact side of dyskinetic p = 0.156, and lesioned side of dyskinetic p = 0.115; one-factor ANOVA). Therefore, mean values for the first KCl-evoked dopamine release before L-DOPA is presented.
To investigate how KCl-evoked dopamine release in the striatum is affected by a local injection in itself and whether the response is affected by the duration of time, saline (0.9% NaCl) was locally injected into the intact (240 nL) and dopamine-lesioned (480 nL) striatum. No differences were detected for dopamine peak amplitudes when compared before and after local saline injections neither in the intact nor in the dopamine-lesioned striata (Fig. 2a and c) .
Dopamine release in dopamine-depleted animals upon L-DOPA loading
Normal versus intact striatum of dopamine-lesioned animals Before application of L-DOPA, KCl-evoked dopamine release in normal and intact striatum of dopamine-lesioned animals did not differ in peak amplitude and resulted in increased extracellular dopamine releases of approximately 5 lM (Fig. 2a) . After local L-DOPA loading, the first evoked dopamine release was significantly increased both in the normal to approximately 15 lM (p = 0.047, F 2,30 = 5.474, one-way ANOVA; Fig. 2a and b) and the intact striatum of the unilaterally dopamine-depleted animals to approximately 25 lM (p = 0.007, F 2,30 = 5.616, one-way ANOVA; Fig. 2a) . The increase found in extracellular dopamine in the intact side was moderately but non-significantly elevated compared with normal striatum. The second KCl-evoked release produced significantly increased dopamine peak amplitude in the normal striatum (p = 0.014, F 2,30 = 5.474, one-way ANOVA; Fig. 2a ). Increased dopamine releases were also measured in the intact side of the dopamine-depleted animal, although these were not significantly different compared with before L-DOPA application.
The onset of dopamine release (T rise ), that is, the time required for the dopamine release to reach its maximum concentration is described to evaluate kinetics of dopamine releases. The reuptake (T 50 ) is defined as the time required for the extracellular dopamine levels to decrease to 50% of the maximal concentration. Both the onset and the reuptake were in the same range in the normal striatum and the intact side of the dopamine-depleted brain, with onset occurring within around 30 s (Fig. 3a) and reuptake occurring between 50 and 60 s (Fig. 3b) . None of these parameters were affected by the application of L-DOPA.
Dopamine-lesioned striatum
In the dopamine-depleted striatum, KCl stimulation resulted in elevated extracellular dopamine peak amplitude at approximately 150 nM before L-DOPA loading ( Fig. 2c  and d) . After L-DOPA application, the first KCl ejection significantly increased extracellular dopamine compared with before with mean peak amplitude around 400 nM (p = 0.005, F 2,65 = 5.735, one-way ANOVA; Fig. 2c ). The second KCl stimulation after L-DOPA loading resulted in elevated, although non-significant, increases of extracellular dopamine compared with before L-DOPA (Fig. 2c) .
Dopamine release in dopamine/serotonin-lesioned animals upon L-DOPA loading
Intact side of dopamine/serotonin-lesioned animals In the intact striatum of the dopamine/serotonin-lesioned animal, the dopamine release reached concentrations comparable to normal and intact side of the dopamine-depleted striatum prior to L-DOPA application (Fig. 4a) . Furthermore, Fig. 2 Dopamine release (lM) before and after L-DOPA or saline loading in normal and unilaterally dopamine-depleted rats. KCl-evoked dopamine release was increased upon striatal L-DOPA (2.5 mM) administration compared to before L-DOPA was given in normal (a, b) and intact striatum of dopamine-lesioned animals (a). Increased dopamine release was observed in the dopamine-lesioned striatum after local L-DOPA ejection (12.5 mM; c, d), and the peak amplitude was several-folds lower than in the normal and intact striatum. Saline ejections had no effect on dopamine release. *p < 0.05, **p < 0.01.
an overall trend of increased dopamine release was evident after local L-DOPA administration compared with before (p < 0.001, F = 8.594; two-factor ANOVA), with no differences between the intact sides of dopamine-and dopamine/ serotonin-lesioned animals and normal striatum (p = 0.184; two-factor ANOVA). Although an increase in dopamine release was found after L-DOPA loading in the intact side of dopamine/serotonin-lesioned animals, it was statistically non-significant. However, the dopamine peak amplitudes were similar to those measured in normal animals (Fig. 4a) . Additionally, T rise was similar to that monitored in normal striatum and intact side of dopamine-depleted brain, and ranged around 25-40 s with no differences in onset before and after L-DOPA infusion (Fig. 3a) . The reuptake (T 50 ) Fig. 3 Onset (T rise ) and reuptake (T 50 ) of KCl-evoked dopamine release in the normal and intact striatum of dopamine-, dopamine/serotonin-lesioned and dyskinetic animals. T rise was not affected by L-DOPA application in any of the animals (a). T 50 was prolonged in the intact striatum of dyskinetic animals before L-DOPA loading compared with normal and dopamine-depleted animals (b). *p < 0.05. Fig. 4 Dopamine release (lM) in dopamine/serotonin-lesioned animals after L-DOPA loading. Local L-DOPA (2.5 mM) administration did not significantly increase the KCl-evoked dopamine release in the intact striatum of dopamine/serotonin-depleted animals, as seen in normal as well as in the intact striatum of unilaterally dopamine-depleted animals (a). Increased dopamine release was observed in the dopamine lesioned striatum after L-DOPA (12.5 mM) loading (b), but not in the dopamine/serotonin-depleted striatum (b, c). *p < 0.05, **p < 0.01. occurred in 50-70 s and was not affected by the L-DOPA loading (Fig. 3b) . Dopamine/serotonin-lesioned striatum Recordings performed in the dopamine/serotonin-lesioned striatum revealed dopamine peak amplitudes equivalent to those measured in the dopamine-lesioned striatum before L-DOPA application (Fig. 4b ). Significant differences in dopamine concentration was detected when comparing the recordings in the two lesion protocols (p = 0.015, F = 6.059, two-factor ANOVA), and also when comparing measurements performed before or after L-DOPA loading (p = 0.005, F = 5.627), although no interaction was seen between factors (p = 0.077). However, after L-DOPA loading, the increased dopamine peak amplitude found in the dopamine-depleted striatum was abolished in the dopamine/serotonin-lesioned striatum (Fig. 4a-c) . The peak amplitude induced by the second KCl-injection was not different from prior to L-DOPA injection, and was significantly reduced compared with the second measurement made in dopamine-depleted striatum after L-DOPA application (p = 0.030; F 1,33 = 5.125, oneway ANOVA; Fig. 4b) . Thus, application of L-DOPA did not affect the dopamine peak amplitude in the dopamine/ serotonin-denervated side.
Dopamine release in L-DOPA-induced dyskinetic animals upon local L-DOPA loading Behavioral assessment of animals with L-DOPA-induced dyskinesia revealed moderate to severe dyskinesia in 80% of the cases, which is in accordance with previous studies. Animals were matched, and subjects that expressed similar degrees of dyskinesia were selected for this study. The selected animals expressed AIMs scores of 32.80 ± 2.06 when evaluated 10 days after the chronic L-DOPA treatment period.
Intact striatum of dyskinetic animals
The basal KCl-evoked striatal dopamine release was not affected by the chronic L-DOPA treatment in the intact hemisphere of dyskinetic animals, when compared with the intact side of L-DOPA naïve dopamine-lesioned and normal animals (Fig. 5a ). An overall increase in dopamine peak amplitude was seen after local L-DOPA loading compared with before (p < 0.001, F = 10.618, two-factor ANOVA), with variations between animal models (p < 0.001, F = 9.186, two-factor ANOVA), but without interaction between factors (p = 0.074). The first KCl-evoked release performed after L-DOPA loading in the intact striatum of dyskinetic animals gave rise to non-significant increase in extracellular dopamine when compared with dopamine release gained before the drug application (Fig. 5a ). The dopamine peak amplitude was significantly lower in these animals than in the intact striatum of L-DOPA naïve unilaterally dopamine-lesioned brain (p = 0.015, F 2,32 = 4.811, one-way ANOVA; Fig. 5a ). In contrary to observations made in the intact side of L-DOPA naïve animals, the intact striatum of the dyskinetic animals displayed difficulties when being re-challenged; the second KCl ejection did not always produce measurable dopamine after L-DOPA loading. Consequently, the second KCl ejection resulted in reduced dopamine peak amplitude compared with normal (p = 0.039) and intact side of the dopamine-lesioned animals (p = 0.023, F 2,31 = 5.125, oneway ANOVA; Fig. 5a ).
In the intact side of dyskinetic animals, T rise was modestly prolonged to approximately 50 s for dopamine release evoked before L-DOPA loading compared with 20-30 s, as observed in the intact sides of lesioned and normal L-DOPA naïve animals (Fig. 3a) . The reuptake was significantly Fig. 5 Effects of L-DOPA on dopamine release (lM) in dyskinetic animals. KCl-evoked dopamine release is not affected by L-DOPA loading in the intact (2.5 mM; a) and lesioned (12.5 mM; b) striata of dyskinetic animals. The KCl-evoked dopamine release after L-DOPA application produced lower peak amplitude than in normal (a) and dopamine-depleted L-DOPA-naïve animals (a, b). *p < 0.05, **p < 0.01, ***p < 0.001. Fig. 3b ). After L-DOPA loading, the reuptake was not different from the times observed in the intact side of lesioned and normal L-DOPA naïve animals (60-70 s).
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Lesioned striatum of dyskinetic animals
The development of dyskinesia did not affect the basal dopamine release produced in the dopamine-lesioned side compared with measurements performed in L-DOPA naïve dopamine-lesioned striatum (Fig. 5b) . However, significant differences were found in peak amplitude of dopamine before and after local L-DOPA loading (p = 0.033, F = 3.526) and when comparing the lesioned striata of dyskinetic and L-DOPA naïve animals (p < 0.001, F = 22,108) with interaction between the factors (p = 0.010, F = 4,839). Interestingly, L-DOPA application did not affect KCl-evoked dopamine release in the lesioned striatum of dyskinetic animals (Fig. 5b) . In fact, both the first (p = 0.001, F 1,41 = 11.983, one-way ANOVA) and second (p < 0.001, F 1,37 = 14.883, one-way ANOVA) KCl-evoked dopamine release following L-DOPA loading was significantly lower in the lesioned striatum of dyskinetic than in the L-DOPA naïve animals.
Immunohistochemical evaluations
The presence of striatal TH-and SERT-immunoreactivity TH-immunoreactivity was performed to verify dopaminergic denervation of the striatum. The results revealed that no THimmunoreactivity or very few scattered nerve fibers were found in the lesioned hemisphere of all rats included in this study (Fig. 6f-h) .
The SERT-positive nerve fiber density was significantly reduced in the dopamine-depleted hemisphere of animals that had received the serotonergic lesion compared with all other groups (dopamine/serotonin-lesioned striatum vs. normal p < 0.001, intact side of dopamine-lesioned p < 0.001, dopamine-lesioned p = 0.002, intact side of dyskinetic p < 0.001, dopamine-lesioned side of dyskinetic p = 0.001, one-way ANOVA; Fig. 6 ). A robust SERT-positive nerve fiber denervation was also observed in the contralateral hemisphere (intact side of the dopamine/serotonin-lesioned striata vs. normal p < 0.001, intact side of dopamine-lesioned p < 0.001, dopamine-lesioned p = 0.005, intact side of dopamine-lesioned and dyskinetic p < 0.001, dopaminelesioned and dyskinetic p = 0.002, one-way ANOVA; Fig. 6e ). Furthermore, significantly reduced SERT-positive nerve fiber density was found in the 6-OHDA-lesioned compared with normal striatum (dopamine-lesioned p < 0.001, dopamine/ serotonin-lesioned p < 0.001, dopamine lesioned and dyskinetic p < 0.001 vs. normal striata, F 6,91 = 18.682, one-way ANOVA; Fig. 6) . No difference was found between the hemispheres of the same animal, and therefore a similar reduction of serotonergic nerve fiber density was detected in the intact sides of all lesioned animals (intact side of dopamine-lesioned p = 0.001, dopamine/serotonin-lesioned Fig. 6 SERT-(a-e) and TH-(--h) positive nerve fiber density in the striatum. SERT-positive nerve fiber density in normal (a), dopaminelesioned (b), dopamine-lesioned of dyskinetic animals (c), and dopamine/serotonin-lesioned striata (d) demonstrated significantly reduced nerve fiber density in dopamine/serotonin-lesioned striatum compared with all groups (e). Lesion effects were also found in the contralateral striatum of the dopamine/serotonin-lesioned animals, exhibiting significantly reduced levels of SERT-positive nerve fibers (e). In addition, the SERT-positive nerve fiber levels were significantly reduced in both hemispheres of animals receiving a 6-OHDA-lesion compared with normal animals (e). Similar levels of SERT-positive nerve fibers were seen in dyskinetic and L-DOPA naïve dopamine-depleted animals. THimmunoreactivity in the striata of normal (f), dopamine-lesioned (g), and dopamine-lesioned dyskinetic animals (h). No or very few THpositive nerve fibers were found in the striatum of dopamine-lesioned hemispheres. Scale bar = 100 lm. *p < 0.05, ***p < 0.001 compared with normal striatum. Fig. 6e ). Additionally, similar levels of SERTpositive nerve fiber density were detected in the dopaminelesioned striatum of L-DOPA naïve and dyskinetic animals (Fig. 6b, c and e) .
The presence of AADC-positive immunoreactivity in the striatum The presence of AADC-immunoreactivity was studied in sections from dyskinetic, L-DOPA naïve unilaterally dopamine-lesioned, and normal animals at bregma level and at 0.1 mm anterior to bregma, that is, the coordinates for recordings. The results revealed sparsely located small-sized AADC-positive neurons within the striatum. These neurons were found primarily in the dorsal striatum, and more frequently in a dorsoventral direction near the lateral ventricles. Neither the location nor the number of AADCpositive neurons differed between groups at bregma level (p = 0.999, F 6,35 = 0.069, one-factor ANOVA) or at 0.1 mm anterior to bregma (p = 0.536, F 6,29 = 0.859, one-factor ANOVA). The mean number of AADC-positive neurons found per section was between 10 and 15 in all animals (normal=11.56 ± 2.11, dopamine-lesioned=11.20 ± 2.83, intact side of dopamine-lesioned=12.60 ± 2.82, dopaminelesioned side of dyskinetic=12.00 ± 3.02, and intact side of dyskinetic=12.67 ± 2.88).
Discussion
This study presents data supporting that L-DOPA can be converted to dopamine and significantly enhances dopamine release in normal as well as in intact and lesioned hemispheres of dopamine-depleted animals. The release of dopamine upon L-DOPA loading in dopamine-depleted striatum appears to be derived from the serotonergic nerve fibers, as the signal disappeared after a serotonergic lesion. Interestingly, the serotonergic lesion did also affect the dopamine release in the intact striatum. In animals expressing L-DOPA-induced dyskinesia, no evidence for enhanced dopamine release upon L-DOPA application was detected, neither in the intact nor in the dopamine-depleted striatum. In fact, the dopamine release in the dyskinetic animals was significantly attenuated when comparing with L-DOPA naïve unilaterally dopamine-depleted animals. It is well known that L-DOPA can be converted in dopamine nerve terminals (Hefti et al. 1981) ; hence, the increased KCl-evoked dopamine release found in normal and intact striatum of dopaminedepleted animals was expected upon L-DOPA loading. However, these high dopamine levels after L-DOPA administration could neither be demonstrated in intact striata of dyskinetic nor of dopamine/serotonin-lesioned animals. The lack of increased dopamine release in dyskinetic animals might be explained by the chronic L-DOPA treatment, because chronic L-DOPA will cause increased extracellular dopamine levels as determined by microdialysis (Sarre et al. 1994; Miller and Abercrombie 1999; Carta et al. 2006) . However, in vivo chronoamperometry monitors dopamine levels in change from baseline, while microdialysis measures the basal extracellular concentration. Therefore, the abolished effect of KCl-evoked dopamine release found in the present study is presumably reflecting an overall enhanced baseline of extracellular dopamine, leading to downregulated dopamine release via autoreceptors. This was strengthened by the increased T 50 in the intact striatum of dyskinetic animals. In addition, similar results have been achieved in the intact side of dyskinetic rats after a systemic injection of L-DOPA (Lundblad et al. 2009 ).
The attenuated dopamine release found after L-DOPA loading in the intact striatum of dopamine/serotonin-lesioned animals is, however, more confusing. These animals lack the serotonergic nerve fibers but their dopamine nerve fibers are intact, and should thus be able to produce high dopamine levels via the dopamine nerve fibers. However, the dopamine levels were moderately increased. Thus, it seems as serotonergic nerve fibers are important for dopamine production formed from exogenous L-DOPA also in the intact striatum, which is supported by data stating that exogenous L-DOPA can increase the dopamine levels via the serotonergic nerve fibers independent of the presence of dopaminergic nerve fibers (Mizoguchi et al. 1993; Navailles et al. 2010) . However, other techniques, such as rotational behavior, demonstrate that animals rotate contralateral to the dopamine-denervated side upon L-DOPA injection (Hefti et al. 1981; Lundblad et al. 2002; Kääriäinen et al. 2008) . Hence, even if the dopamine release becomes abnormally high with involvement of the serotonin nerve fibers or is not affected by L-DOPA application in intact side, the denervated hemisphere appears to be dominant regarding behavioral outcome in response to exogenous L-DOPA. Consequently, the dopamine levels derived in the intact side appears to have no or minor influence on the dyskinetic behavior.
The potassium-evoked dopamine release as a result of L-DOPA being accumulated in neurons, converted to dopamine, and stored as dopamine in synaptic vesicles can, in the absence of dopamine nerve fibers, occur in serotonergic neurons because these express both AADC and the vesicular monoamine transporter 2 (Arai et al. 1995; Nirenberg et al. 1995; Peter et al. 1995; Yamada et al. 2007 ), a mechanism that has been suggested by several investigators (Sarre et al. 1994; Tanaka et al. 1999; Carta et al. 2006; Carlsson et al. 2007; Eskow et al. 2009; Gregoire et al. 2009 ). The present study supports these data in that the KCl-evoked dopamine releases upon L-DOPA loading were attenuated in the absence of serotonergic nerve fibers in the dopaminedepleted striatum, which previously has been demonstrated using microdialysis (Tanaka et al. 1999; Navailles et al. 2010) . However, utilizing in vivo chronoamperometry, the release amplitude of dopamine upon systemic L-DOPA injection does not correlate with the density of serotonergic nerve fibers (Lundblad et al. 2009 ). This was strengthened by the results in the present paper, where the released dopamine upon L-DOPA loading was enhanced in the dopamine-depleted striatum of L-DOPA naïve but not in dyskinetic animals, although SERT-positive nerve fiber density was similar in these animals. There are contradictory opinions in the matter of serotonergic nerve fiber density in dyskinetic patients, where some claim that markers for serotonergic nerve fiber density is increased in dyskinetic compared with non-dyskinetic patients, whereas others, in line with the present animal study, suggest that no correlation is found between serotonergic nerve fiber density and dyskinesia (Kish et al. 2008; Politis et al. 2010; Rylander et al. 2010) . Although several animal studies have suggested that serotonergic nerve fiber density is correlated to L-DOPAinduced dyskinesia (Tanaka et al. 1999; Kannari et al. 2001; Carlsson et al. 2007 Carlsson et al. , 2009 Carta et al. 2007; Lundblad et al. 2009 ), the present results revealed that the dopamine levels produced by L-DOPA conversion in serotonergic nerve fibers are very low, much below those found in normal striatum. Therefore, if the dyskinetic behavior is depending on overproduction of dopamine as previously suggested Lindgren et al. 2010) , the conversion of L-DOPA to dopamine in serotonergic nerve fibers appears not to be the major mechanism involved in dyskinesia. Even though the pharmacological evidence using a 5-HT 1A receptor agonist to block release of dopamine as a false transmitter from the serotonergic nerve fibers has been effective (Kannari et al. 2001; Carta et al. 2006; Dupre et al. 2007) , the reduction in dyskinetic behavior might be a masked effect by the 5-HT 1A post-synaptic receptor affecting the cortical input to the striatum, which also has been suggested (Mignon and Wolf 2007) . Thus, involvement of the serotonin system in dyskinesia may include other mechanisms than the conversion of L-DOPA.
Striatal AADC-positive structures was found in striatal neurons, as previously reported (Melamed et al. 1980) . In dopamine-depleted animals, TH-immunoreactivity can be demonstrated in striatal neurons, and approx. half of the THpositive neurons also express AADC, and appears to be striatal output neurons (Darmopil et al. 2008) . Indeed, the presence of AADC in the striatum is of importance for dyskinetic behavior, such that an over-expression of AADC potentiates, while inhibiting AADC activity reverse dyskinetic behavior (Bankiewicz et al. 2006; Buck and Ferger 2008) . However, the striatal AADC-positive neurons were localized close to the ventricle rather than to the lateral striatum, more known to be important for motor output. Furthermore, most of the AADC-positive neurons were located medial to the recording track, and because the application of L-DOPA was very local, these neurons might not exert the main role to convert L-DOPA under these conditions. Taken together, this study demonstrates that L-DOPA can be converted and released as dopamine upon potassium stimulation in the dopamine-but not in the dopamine/ serotonin-lesioned striatum. Furthermore, the peak amplitude of dopamine was increased in normal striatum and bilaterally in unilaterally dopamine-depleted animals, but abolished in animals expressing L-DOPA-induced dyskinesia, after local L-DOPA administration, although the lesioned animals had similar density of SERT-positve nerve fibers. Thus, even though serotonergic nerve fibers are capable of converting L-DOPA into dopamine, it might not serve as the major mechanism of dyskinesia, since the dopamine release upon L-DOPA administration was attenuated in dyskinetic animals compared with L-DOPA naïve animals.
